Color Duplex Doppler US can Follow up the Response of Radioiodine in Graves' Disease by Evaluating the Thyroid Volume and Peak Systolic Velocity

Nenhuma Miniatura disponível
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
GEORG THIEME VERLAG KG
Autores
SANTOS, Thiago Adler Ralho Rodrigues
OZAKI, Claudia Okanobo
Citação
ULTRASCHALL IN DER MEDIZIN, v.41, n.6, p.658-667, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose The objective of this study was to prove the efficacy of Doppler ultrasonography (US-Doppler) in the follow-up of patients with GD treated with radioactive iodine. Methods 97 patients (77 female and 20 male) with a mean age of 42 years (SD +/- 15) and with prior diagnosis of GD were treated with radioiodine. In total, 88.5 % achieved euthyroidism or hypothyroidism after treatment. The study was documented before treatment and one, three, and six months after treatment with radioactive iodine (131I) by a single investigator. The volume, echogenicity, echotexture and vascularization of the glands as well as the peak systolic velocity (PSV) of the inferior thyroid arteries were evaluated and compared with the laboratory data. Results Thyroid volume and PSV had a statistically significant correlation with hormone levels (p < 0.05). The mean pre-dose therapeutic thyroid volume was 43.01 +/- 3.88 cm(3) and was 11.58 +/- 11.26 cm(3) 6 months after treatment. The mean PSV before 131I was 90.06 +/- 44.13 cm/s and decreased significantly over time (p < 0.001). Six months after the therapeutic dose, the mean PSV was 32.95 +/- 16.36 cm/s. However, the subjective parameters did not have a significant correlation with the normalization of the thyroid hormones. Conclusion Doppler US was useful for monitoring the therapeutic response of GD patients after treatment with radioiodine by evaluating the thyroid volume and peak systolic velocity.
Palavras-chave
thyroid gland, hyperthyroidism, Graves' disease, duplex-doppler ultrasound, radioiodine therapy (131I)
URI
https://observatorio.fm.usp.br/handle/OPI/39154
Referências
  1. Alzahrani AS, 2012, ENDOCR PRACT, V18, P567, DOI 10.4158/EP11170.RA
  2. Ballal S, 2017, INDIAN J MED RES, V145, P358, DOI 10.4103/ijmr.IJMR_1158_14
  3. Bartalena L, 2016, J ENDOCRINOL INVEST, V39, P1445, DOI 10.1007/s40618-016-0516-7
  4. Bogazzi F, 1996, J ENDOCRINOL INVEST, V19, P603, DOI 10.1007/BF03349025
  5. Bogazzi F, 1997, THYROID, V7, P541, DOI 10.1089/thy.1997.7.541
  6. Caruso G, 2000, EUR J RADIOL, V36, P5, DOI 10.1016/S0720-048X(00)00147-9
  7. Castagnone D, 1996, AM J ROENTGENOL, V166, P203, DOI 10.2214/ajr.166.1.8571877
  8. Chen L, 2012, J INT MED RES, V40, P640, DOI 10.1177/147323001204000226
  9. Chen Yangchun, 2017, Asia Ocean J Nucl Med Biol, V5, P44, DOI 10.22038/aojnmb.2016.7401
  10. Cosgrove D, 2017, ULTRASOUND MED BIOL, V43, P4, DOI 10.1016/j.ultrasmedbio.2016.06.022
  11. Dighe M, 2017, MED ULTRASON, V19, P79, DOI 10.11152/mu-980
  12. Donkol RH, 2013, WORLD J RADIOL, V5, P178, DOI 10.4329/wjr.v5.i4.178
  13. Eising EG, 2002, CLIN RADIOL, V57, P646, DOI 10.1053/crad.2001.0903
  14. Hasham A, 2012, IMMUNOL RES, V54, P204, DOI 10.1007/s12026-012-8302-x
  15. Höfling Danilo Bianchini, 2008, Radiol Bras, V41, P409, DOI 10.1590/S0100-39842008000600012
  16. Karakas O, 2014, CLIN IMAG, V38, P1, DOI 10.1016/j.clinimag.2013.06.010
  17. Kim TK, 2015, ULTRASONOGRAPHY, V34, P292, DOI 10.14366/usg.14059
  18. Kumar KVSH, 2009, W INDIAN MED J, V58, P566
  19. Lang BHH, 2017, RADIOLOGY, V285, P1011, DOI 10.1148/radiol.2017162776
  20. Macedo TAA, 2007, ACTA RADIOL, V48, P412, DOI 10.1080/02841850701280791
  21. Macedo TAA, 2007, BRIT J RADIOL, V80, P625, DOI 10.1259/bjr/69016171
  22. Maia AL, 2013, ARQ BRAS ENDOCRINOL, V57, P205, DOI 10.1590/S0004-27302013000300006
  23. Markovic V, 2007, J CLIN ENDOCR METAB, V92, P3547, DOI 10.1210/jc.2007-0879
  24. Menconi F, 2014, AUTOIMMUN REV, V13, P398, DOI 10.1016/j.autrev.2014.01.013
  25. Mizokami T, 2016, EUR THYROID J, V5, P201, DOI 10.1159/000448398
  26. MULLER HW, 1985, KLIN WOCHENSCHR, V63, P706, DOI 10.1007/BF01733114
  27. Nagasaki T, 2007, BIOMED PHARMACOTHER, V61, P472, DOI 10.1016/j.biopha.2007.02.002
  28. Nagasaki T, 2010, BIOMED PHARMACOTHER, V64, P113, DOI 10.1016/j.biopha.2009.04.038
  29. Ozturk M, 2017, RADIOL MED, V122, P960, DOI 10.1007/s11547-017-0801-3
  30. Peters H, 1996, EUR J CLIN INVEST, V26, P59, DOI 10.1046/j.1365-2362.1996.98243.x
  31. Pishdad P, 2017, J BIOMED PHYS ENG, V7
  32. RALLS PW, 1988, AM J ROENTGENOL, V150, P781, DOI 10.2214/ajr.150.4.781
  33. Ross DS, 2016, THYROID, V26, P1343, DOI 10.1089/thy.2016.0229
  34. Saleh A, 2001, ULTRASOUND MED BIOL, V27, P1137, DOI 10.1016/S0301-5629(01)00410-0
  35. Santos TARR, 2014, HEALTH, V6, P1487
  36. Sapienza MT, 2015, CLIN NUCL MED, V40, P715, DOI 10.1097/RLU.0000000000000840
  37. Solbiati L, 1995, ULTRASOUND SUPERFICI
  38. Uchida T, 2010, ENDOCR J, V57, P439, DOI 10.1507/endocrj.K09E-263
  39. Ueda M, 2005, CLIN ENDOCRINOL, V63, P657, DOI 10.1111/j.1365-2265.2005.02397.x
  40. Varadhan Lakshminarayanan, 2016, Indian J Endocrinol Metab, V20, P866
  41. Vieira LD, 2011, ARQ BRAS ENDOCRINOL, V55, P696, DOI 10.1590/S0004-27302011000900005
  42. Vitti P, 1995, J ENDOCRINOL INVEST, V18, P857, DOI 10.1007/BF03349833
  43. Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707
  44. Zhao X, 2012, PLOS ONE, V7
  45. Zuhur SS, 2014, ENDOCR PRACT, V20, P310, DOI 10.4158/EP13300.OR
  46. Zuhur SS, 2012, CLINICS, V67, P125, DOI 10.6061/clinics/2012(02)06

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/44